Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [57]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 293
Structure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Dipeptidyl peptidase IV, a kidney brush-border serine peptidase
Kenny, A. J., Booth, A. G., George, S. G., Ingram, J., Kershaw, D., Wood, E. J., & Young, A. R. (1976) · Biochemical Journal · doi:10.1042/bj1570169 · Cited by 254
Cited by
Items 701–798 of 798
Cheng, X. W., Murohara, T., & Kuzuya, M. (2013) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2013.10.003 · Cited by 2
“However, it was reported that after secretion, GLP-1 is targeted rapidly by serine protease dipeptidyl dipeptidase-4 for degradation to GLP-1 (9-36), a weak antagonist of GLP-1R without incretin activity [1,5].”
BackgroundManagement of type 2 diabetes mellitus in chronic kidney disease
Maffioli, P., & Derosa, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.977993 · Cited by 2
Kahal, H. (2013) · Repository@Hull (Worktribe) (University of Hull) · Cited by 2
Li, S., Guan, C., Wang, Y., Chen, H., Li, W., Wang, S., Zhang, C., & Xing, X. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250206 · Cited by 2
“The discovery of glucagon-like peptide-1 (GLP-1), an intestinal hormone involved in glucose homeostasis [4,5],and a DPP-IV substrate [6–8] has highlighted the role of DPP-IV in glycemic regulation.”
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Fujishima, Y., & Maeda, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00015-5 · Cited by 1
Inkretine: Gibt es kardiovaskuläre Effekte?
Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1
“tische Nutzbarkeit von GLP-1 wegen dessen schnellen enzymatischen Abbaus durch die Dipeptidylpeptidase-(DPP-)4 als impraktikabel [12, 13].”
BackgroundThe Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Glucagonlike Peptides 1 and 2, Enteroglucagon, Glicentin, and Oxyntomodulin
Holst, J. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50148-3 · Cited by 1
Self-citationColonic delivery of nutrients for management of blood glucose in type 2 diabetes patients
Szewczyk, J. R., Giannone, J., Marcuard, S. P., Kindel, T. L., Tso, P., & Nolan, R. D. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i1.283 · Cited by 2
“In fact, GLP-1 has a plasma halflife of 1-2min [41;42].”
BackgroundСаприна, Т. В., Timokhina, Y. S., Мусина, Н. Н., Prokhorenko, T. S., Таширева, Л. А., & Goncharevich, O. K. (2013) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2013-3-132-147 · Cited by 2
Kardiovaskuläre Effekte inkretinbasierter Therapien
Lehrke, M., & Marx, N. (2012) · Herz · doi:10.1007/s00059-012-3599-8 · Cited by 1
Lai, Z., Liang, Z., Yan, L. Y., Qian, X., Jiang, H., & Zhong, W. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.113995 · Cited by 1
Abdelhamid, A., Youssef, M., & Saber, S. (2022) · Delta University Scientific Journal · doi:10.21608/dusj.2022.275439 · Cited by 2
“Dipeptidyl peptidase-4 (DPP-4) enzyme, a highly specialized amino-peptidase, presents in intestinal brush-border membranes, plasma, kidney and on a subset of T lymphocytes, the surface of capillary endothelial cells and hepatocytes (Deacon, Johnsen, & Holst, 1995).”
BackgroundGut-Derived Hormones—Cardiac Effects of Ghrelin and Glucagon-Like Peptide-1
Ruozi, G., Bortolotti, F., & Recchia, F. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803111-7.00006-3 · Cited by 6
Cao, H., Guo, W., Yu, Y.-X., Wang, H., Tang, Q., Li, S., & Zheng, X. (2017) · Journal of Theoretical and Computational Chemistry · doi:10.1142/s0219633617500717 · Cited by 1
Pan, X., Xu, Q., Chen, J., Wang, T., Zhang, M., Wang, H., & Gao, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10432 · Cited by 3
Approaches to _-Cell Regeneration and Neogenesis
Campbell, S., & Macfarlane, W. M. (2007) · CRC Press eBooks · doi:10.3109/9781420016512-18 · Cited by 1
Normal Insulin Secretion in Humans
Utzschneider, K. M., Porte, D., & Kahn, S. E. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0205 · Cited by 1
Hinke, S. A., Pederson, R. A., & McIntosh, C. H. S. (2006) · Springer eBooks · doi:10.1007/0-387-32824-6_13 · Cited by 1
“In this regard, the development of techniques capable of recognizing the intact N-terminus of GLP-1 or GIP have proven highly useful ( Deacon et al 1995, 2000; Wolf et al 2004).”
Shestakova, M. V., & Vikulova, O. K. (2007) · Diabetes Mellitus · doi:10.14341/2072-0351-5908 · Cited by 1
Vilsbøll, T. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.1.13 · Cited by 2
Shi, W. (2004) · VTechWorks (Virginia Tech) · Cited by 1
Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
Effect of different surgical weight-loss interventions and ethnicity on GLP-1 secretion
Al-Rasheid, N. (2018) · UCL Discovery (University College London) · Cited by 1
Gastrointestinal signals regulating appetite in humans
Oesch, S. (2005) · edoc (University of Basel) · doi:10.5451/unibas-003768417 · Cited by 1
Athanasia, K., Marina, S., & Stavros, I. (2011) · InTech eBooks · doi:10.5772/20616
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
In vivo Regulation of Human Islet Hormone Secretion by Glucagon-Like Peptide-1
D’Alessio, D. A., & Ensinck, J. W. (1997) · Frontiers in diabetes · doi:10.1159/000194733
糖尿病の治療戦略として期待されるglucagon-like peptide-1 (GLP-1)
立石, カ. (1999) · 臨床化学 · doi:10.14921/jscc1971b.28.4_167
Mehl, U. (2012) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15035
The efficacy of application of vildagliptin in the patints presenting with co-morbid pathology
Vertkin, A. L., Магомедова, А. Ю., Мычка, В. Б., Прохорова, Ю. В., & Nosova, A. V. (2012) · Problems of Endocrinology · doi:10.14341/probl201258341-45
GLP-1 REGULATES PROLIFERATION OF GLP-1 SECRETING CELLS THROUGH A FEEDBACK MECHANISM
Mohamed, M. A. (2010)
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Саприна, Т. В., Гудкова, Т. К., Столярова, В. А., Мартынова, С. Ю., Дударькова, Н. Г., Ярошевская, Т. Г., & Латыпова, В. Н. (2012) · Problems of Endocrinology · doi:10.14341/probl201258575-79
Exenatide: A Novel Therapeutic Approach for Type 2 Diabetes Mellitus
McCord, A. D. (2005) · Journal of Pharmacy Technology · doi:10.1177/875512250502100402
Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s4535
ON THE DETECTION AND MANAGEMENT OF URINARY BLADDER CARCINOMA
Thorstenson, A. (2008) · Figshare
Adolescent type 1 diabetes : Eating and gastrointestinal function
Lodefalk, M. (2009) · Örebro University Library (Örebro University)
Gastroduodenal feeding after gastric bypass: a response to the comment by Jorgensen et al.
Tamboli, R. A., & Abumrad, N. N. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00279.2011
“Furthermore, infusion of GLP-19–36, the dipeptidyl peptidase IV degradation product (4), into humans has not been shown to have an insulinotropic or glucoregulatory effect, nor to antagonize the effects of GLP-17–36 (14).”
BackgroundIncretin mimetics: type 2 diabetes therapy beyond glucose control
Gallwitz, B. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00325.x
Köthe, L. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1062
Nanoparticles for Pancreatic Islet Imaging
Kim, M. J., Hwang, Y. H., & Lee, D. Y. (2015) · Biosystems & biorobotics · doi:10.1007/978-3-319-21813-7_2 · Cited by 1
Wootten, D. L., Savage, E. E., Valant, C., May, L. T., Sloop, K. W., FICORILLI, J. V., Showalter, A. D., Willard, F. S., Christopoulos, A., & Sexton, P. M. (2012)
Shamlan, G. H. (2016) · University of Surrey Open Research repository
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
“Similarly to GIP, both exogenous and endogenous GLP-1 is N-terminally degraded in vivo by DPP-4 (Figure 3B), yielding the non-insulinotropic metabolites GLP-1(9-36) amide and GLP-1(9-37) (Figure 1) (Deacon et al., 1995a; Deacon et al., 1995b; Kieffer et al., 1995).”
BackgroundGABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator
Babateen, O. (2016) · Uppsala University Publications (Uppsala University) · Cited by 1
Gut peptides in gastrointestinal motility and mucosal permeability
Halim, M. A. (2016) · Uppsala University Publications (Uppsala University)
Johnston, K. L. (2003) · University of Surrey Open Research repository
The Role of Incretins in Insulin Secretion
Salehi, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_4-1
Endocrinology of the Gastrointestinal Tract and Modulation of Satiety
Burcelin, R., & Cani, P. D. (2008) · CRC Press eBooks · doi:10.1201/9780849381829.ch11
Incretin hormones as a target for therapy
Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2
Self-citationAbbreviated Title: Extra-Pancreatic Effects of GLP-1
Abu‐Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., & Elahi, D. (2009)
Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders
Fedele, E. (2016) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000e151
“A milestone in the understanding of the physiological roles of the GLP-1/GLP-1R system was the isolation and characterization of the DPP-IV resistant, BBB permeable GLP-1R selective agonist exendin-4 and the selective antagonist exendin-(9-39) that permitted, in addition to in vitro experiments, to initiate various in…”
BackgroundInfluentialThe preproglucagon derived peptides and energy homeostasis
Parker, J. (2013) · doi:10.25560/10956
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
Novel Enteroendocrine Cell Receptors Regulating Incretin Secretion and Glucose Homeostasis
Flock, G. B. (2012) · TSpace (University of Toronto)
Targeting the intestinal L-cell for obesity and type 2
Wewer, N. J., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2014)
Self-citationThe Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism
Ip, W. (2014) · TSpace (University of Toronto)
Role of Fatty Acid Transport Proteins in Oleic Acid-induced Secretion of Glucagon-like Peptide-1
Poreba, M. (2011) · TSpace (University of Toronto)
Signaling pathways of the endogenous glucagon-like peptide-2 (GLP-2) receptor
Walsh, N. (2001) · TSpace (University of Toronto)
Nedogoda, S. V. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-4-89-92
The effect of fermentable dietary fiber on glucose tolerance and immune function in dogs
Massimino, S. (1997) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3ww77426
Endocrine Mechanisms in Obesity
Fischer, K., & Müller, T. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54852-6.00013-6
Insulin sensitivity is mediated by glucose in the hepatoportal region in the rat
Johnson, H. M. (2017) · The Sydney eScholarship Repository (The University of Sydney)
Martins, F. L. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2019.tde-16102019-112906
Саприна, Т. В., Гудкова, Т. К., Stolyarova, V. A., Martynova, S. Y., Дударькова, Н. Г., Ярошевская, Т. Г., Kabirova, Y. A., Павленко, О. А., & Ворожцова, И. Н. (2011) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2011-6-114-119
Elucidating the Efficacy of Clinical Drugs Using FMO
Arulmozhiraja, S., Tokiwa, H., & Shimano, H. (2021) · Springer eBooks · doi:10.1007/978-981-15-9235-5_16
The Role of Incretins in Insulin Secretion
Salehi, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_4
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00035-6
Incretin Mimetics in the Treatment of Type 2 Diabetes Mellitus
Holst, J. J. (2006) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2006.00.01.1g · Cited by 1
Self-citationWilliams, J. A. (2021) · doi:10.3998/panc.2021.06
De, A. (2012) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-1-4614-4875-4_1
Abshire, K. M., & Leggio, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823453-2.00013-8
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Łupina, M., & Listos, J. (2023) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2023-0040
Saviano, A., Apta, B. H. R., Tull, S. P., Pezhman, L., Fatima, A., Mete, A., Sevım, M., Chimen, M., Schettino, A., Marigliano, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618151
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Regulation of Feeding Behavior by Glucagonlike Peptide 1 (GLP-1)
Vuguin, P. M., & Charron, M. J. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50136-7
Glucagon-like Peptides and Insulin Sensitivity
Holst, J. J., & Knop, F. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_13
Self-citationInflammation intestinale et diabète de type 2 : effet du Resveratrol
Dao, T. M. A. (2011) · theses.fr (ABES) · doi:10.70675/ba3c8576z889ez4199zb7d6z98de312b9efb
Α-gustducine intestinale : implication dans l'obésité et le diabète de type 2
Gléau, L. L. (2021) · theses.fr (ABES) · doi:10.70675/dc436e75zb6d2z4bb4zb9a1z17b025f205a6
Xu, J., Zhou, A., Xu, M., Chen, Q. W., Xu, C., Li, J., Li, N., Li, Z., Wu, G., Zhang, W., et al. (2026) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.6c00052
Meftah, A., Yoade, B., Cowart, C., Choi, A., Popoola, O., Afe, O., Efremoff, S., Ezema, C., Johnson, B. O., Lawrence, J., et al. (2026) · Cureus · doi:10.7759/cureus.109089
“Nevertheless, native GLP-1 exhibits a brief half-life (approximately one to two minutes) as a result of quick enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4) [42,43].”
BindingDB (2012) · UC San Diego · doi:10.7270/q24f1r8d
BindingDB (2006) · UC San Diego · doi:10.7270/q2s180qj
Signalling and Regulation of the Glucagon-like Peptide-1 receptor
Lu, J. N. (2014) · Figshare
Metadata
- Authors
- Deacon, C. F., Johnsen, A. H., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-03
- Volume
- 80
- Issue
- 3
- Pages
- 952-957
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068183831
- Cited by
- 792
- References
- 28
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 24 · 2023: 10 · 2022: 14 · 2021: 24 · 2020: 18 · 2019: 34 · 2018: 25 · 2017: 37 · 2016: 41 · 2015: 22 · 2014: 27 · 2013: 40 · 2012: 42
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- glucagon-like peptide-1, dipeptidyl peptidase IV, human plasma, peptide metabolism, endogenous metabolites
- MeSH terms
- Chromatography, High Pressure Liquid, Female, Glucagon, Humans, Male, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.